Marinus Pharmaceuticals Inc (MRNS)

[Titan V]

@AF_Biotech posted that (as you may know very well). He is bullish on SAGE and has been dismissive of MRNS.

Re: oral formulation of Ganaxolone, they failed two p3 trials in 2016 because of low oral bioavailability in the smaller dosage used then. Upcoming PPD data is IV based. It will be more potent. Ganaxolone is also going to be Captisol-enabled, just like SAGE-547 was. Even for oral formulation, they (Marinus) are planning to launch the Amaryllis study using a higher dosage.

The CDKL5 data that was reported in September last year produced very good results. They have improved their oral Ganaxolone as you can see.

Is it a sure thing? I can’t say. No one can. But I like the odds for upcoming PPD data.